Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: Kidney Int. 2014 Oct 29;87(4):828–838. doi: 10.1038/ki.2014.350

Figure 2.

Figure 2

(A) Frequencies of regulatory T cells (CD4+CD25+++FOXP3+ T cells) at baseline, 6 months, 12 months and 24 months post-randomization comparing between TAC maintained and SRL converted group shown in absolute number of cells (Mean ± SD) per microliters of PBMC (Left panel) or percentage of cells (Mean ± SD) within the CD4 T cells (Right panel). (B) Gating strategy and median fluorescent intensity of FOXP3 in CD4+CD25+++FOXP3+ T cells at baseline, 6 months, 12 months and 24 months post-randomization comparing between TAC maintained and SRL converted group. TAC, Tacrolimus maintained group; SRL Sirolimus converted group; Tregs, regulatory T cells; PBMC. Peripheral Blood Mononuclear Cell; MFI, median fluorescent intensity.

HHS Vulnerability Disclosure